

Date: 7th April, 2022

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir/Madam,

Sub: Mistake in selecting date of press release on NSE Digital Portal

Ref: Company's Press Release dated 7th April, 2022 - USFDA Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg.

This is to inform the exchange that there was mistake in selecting the date of press release i.e. **instead of selecting 7th April, 2022 as date of press release**, 31st March, 2022 was selected on NSE Digital Portal in the above referred matter.

We confirm that there is no change in the press release submitted to the exchange.

We request you to kindly take the same on record and arrange to correct the subject matter of announcement appearing on the exchange's website at the earliest.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in
CIN : L24230GJ2010PLC061123